Skip to main content

Table 5 Overall survival by nab-paclitaxel cohort and response

From: 18F-FDG PET/CT response in a phase 1/2 trial of nab-paclitaxel plus gemcitabine for advanced pancreatic cancer

 

nab-Paclitaxel Dose

100 mg/m2

125 mg/m2

All PET-evaluable patients, n

13

38

 Median OS, months

10.9

15.6

Patients with a CMR or PMR, n

10

38

 Median OS, months

11.4

15.6

All patients, n

20

44

 Median OS, months

9.3

12.2a

  1. aData previously published [22]
  2. CMR complete metabolic response, OS overall survival, PET positron emission tomography, PMR partial metabolic response
Back to article page

Cancer Imaging

ISSN: 1470-7330

Contact us